Eikon Therapeutics two board members resign
Eikon Therapeutics, Inc. reported that board members Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026.
Rhea-AI Filing Summary
Eikon Therapeutics, Inc. reported that board members Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026. The company states that their resignations were not due to any disagreement regarding operations, policies, or practices.
Eikon Therapeutics is a Delaware corporation whose common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol EIKN. The report documenting these director changes is signed by Chief Financial Officer Alfred Bowie, Ph.D., on August 3, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective resignation date: July 31, 2026
Report signature date: August 3, 2026
Common stock par value: $0.0001 per share
3 metrics
Effective resignation date
July 31, 2026
Effective date of the resignations of Leon Chen, Ph.D. and Joshua Wolfe from the Board of Directors
Report signature date
August 3, 2026
Date on which CFO Alfred Bowie, Ph.D. signed the report on behalf of the company
Common stock par value
$0.0001 per share
Par value of Eikon Therapeutics, Inc. common stock listed on The Nasdaq Stock Market LLC
Key Terms
Emerging growth company, pre-commencement communications, par value
3 terms
Emerging growth company regulatory
"405 of this chapter)... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
pre-commencement communications regulatory
"Pre-commencement communications pursuant to Rule 14d-2(b)..."
par value financial
"Common Stock, $0.0001 par value per share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board changes did Eikon Therapeutics (EIKN) disclose?
Eikon Therapeutics disclosed that Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026. The company states that their departures were not due to disagreements over operations, policies, or practices.
When did the EIKN director resignations become effective?
The resignations of Eikon Therapeutics directors Leon Chen, Ph.D. and Joshua Wolfe became effective on July 31, 2026. This effective date is specifically identified as the point at which both individuals ceased serving on the Board of Directors.
Did Leon Chen or Joshua Wolfe resign over disagreements with Eikon Therapeutics (EIKN)?
No. Eikon Therapeutics states that Leon Chen, Ph.D. and Joshua Wolfe did not resign because of any disagreement with the company. This includes matters relating to its operations, policies, or practices, according to the company’s disclosure.
Who signed the EIKN report regarding the director resignations?
The report detailing the resignations was signed by Alfred Bowie, Ph.D., the company’s Chief Financial Officer, on August 3, 2026. His signature indicates he was the duly authorized officer executing the disclosure on behalf of Eikon Therapeutics.
On which exchange is Eikon Therapeutics (EIKN) listed and what is its stock type?
Eikon Therapeutics’ common stock, with a par value of $0.0001 per share, trades on The Nasdaq Stock Market LLC under the ticker symbol EIKN. This listing information is provided alongside the director change disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
